New Research Suggests Skin Test Can Detect Dementia with Lewy Bodies

May 22, 2024 Many people who have dementia with Lewy bodies (DLB) experience delay and difficulty with receiving an accurate diagnosis, often seeing multiple specialists before being correctly diagnosed. In […]
Read More

New Research Supports Nuplazid (Pimavanserin) Use in Parkinson’s Disease Dementia

March 18, 2024 Hallucinations and delusions (also called psychosis) are prominent features of Lewy body dementia (LBD), occurring in both dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). […]
Read More

The U.S. Based DIAMOND Lewy™ Management Toolkit

Originally developed in the UK for dissemination via the National Health Service, the Diamond Lewy™ Management Toolkit provides a comprehensive overview of the management of the complex symptoms of Lewy body […]
Read More

Advancing the Science: New Research Frameworks Proposed for the Biology of Dementia with Lewy Bodies and/or Parkinson’s Disease

Two articles published on January 22, 2024, in The Lancet Neurology journal are proposing complementary but different research frameworks for biological definitions of Lewy body disease, a label reflecting the […]
Read More

Men are at greater risk for Lewy body dementia than women, but why? New study seeks answers

Ece Bayram, MD, PhD. Researcher from the Lewy Body Dementia Association’s Research Center of Excellence at University of California San Diego December 12, 2023 Research suggests men have a higher […]
Read More

Research Update: Digging Deeper into Caregiver Strain—LBD Care Partners Report Elevated Levels of High Blood Pressure, Depression, Chronic Back Pain, and Arthritis

November 3, 2023 Caring for a person with Lewy body dementia (LBD) can be very difficult, For example, cognitive changes in LBD are more likely to involve executive function and […]
Read More

Join LBDA in Supporting the National Plan to End Parkinson’s

Sometimes it feels like LBD is hidden in the shadows of two more common diseases – Alzheimer’s disease and Parkinson’s disease. But did you know that federal funding of LBD […]
Read More

A new biological test may revolutionize diagnosis of Parkinson’s disease and dementia with Lewy bodies

A hallmark brain change associated with both Parkinson’s disease and dementia with Lewy bodies (DLB) is the formation of Lewy bodies in brain cells; Lewy bodies are dense collections of […]
Read More

Clinical Trials: New Data and New Opportunities

April 5, 2023 This is an exciting time to follow clinical research in Lewy body dementia. This month we are highlighting updates from recent studies, along with new opportunities to […]
Read More

New Clinical Trial: NIA Awards $21M to Study Treatment for DLB

February 8, 2023   The U.S. National Institute on Aging (NIA), part of the National Institutes of Health (NIH), has awarded $21M for a clinical trial in people with dementia […]
Read More

Clinical Trial of E2027 in DLB Fails

At December’s Clinical Trials in Alzheimer’s Disease conference, Eisai reported that its clinical trial of E2027 in dementia with Lewy bodies (DLB) failed to meet its primary objective. Designed as […]
Read More

FDA Approves DaTscan for Dementia with Lewy Bodies

GE Healthcare recently announced the U.S. Food and Drug Administration (FDA) granted marketing approval for its imaging agent, DaTscan, for use in people with suspected dementia with Lewy bodies (DLB). […]
Read More

Mouse Model Study Offers Insights on Positive DLB Trial Results

All people with dementia with Lewy bodies (DLB) experience increasing problems with cognition. A very common issue is reduced attention, caused by loss of brain cells that release a chemical […]
Read More

Should Medicare pay for the new Alzheimer’s treatment?

When the FDA approved aducanumab for early Alzheimer’s disease, they also required an additional clinical trial to generate more data on its safety and effectiveness. (See LBDA’s earlier position statement […]
Read More

NIH funds $35 million study of LBD risk factor

People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary […]
Read More

LBDA Issues Position Statement on Aducanumab

Key Highlights: The FDA approved marketing of aducanumab for the treatment of Alzheimer’s disease under a special accelerated approval process. Aducanumab has not yet been proven to slow the progression […]
Read More

LBDA Research Mentorship Program

The Lewy Body Dementia Association is interested in establishing a Research Mentorship Program. The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced […]
Read More

Statement from LBDA on Hallucination Treatment Rejected by FDA

The Lewy Body Dementia Association is deeply concerned about the recent ruling by the FDA in which it rejected ACADIA Pharmaceutical’s supplemental new drug application for pimavanserin for the treatment […]
Read More

LBD Biomarkers: Progress

LBDA’s Research Centers of Excellence (RCOE) program presented a virtual symposium on “biomarkers” on January 25, 2021.  A biomarker is a biological sign that reveals the presence or severity of […]
Read More

Sitting in the “genetic cross-hairs” of Alzheimer’s and Parkinson’s

Study locates five genes that may play a critical role in Lewy body dementia. Source: National Institutes of Health In a study led by National Institutes of Health researchers, scientists […]
Read More